Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJC50M)

• DTT Name: P53 Y220C mutant (TP53 Y220C)
• Gene Name: TP53
• DTT Type: Clinical trial target; [1]
• UniProt ID: P53_HUMAN
• TTD ID: T69823
• Sequence:
  MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
  DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
  SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
  RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
  SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP
  PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG
  GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
• KEGG Pathway:
  Endocrine resistance (hsa01522)
  Platinum drug resistance (hsa01524)
  MAPK signaling pathway (hsa04010)
  Sphingolipid signaling pathway (hsa04071)
  Cell cycle (hsa04110)
  p53 signaling pathway (hsa04115)
  Mitophagy - animal (hsa04137)
  PI3K-Akt signaling pathway (hsa04151)
  Apoptosis (hsa04210)
  Longevity regulating pathway (hsa04211)
  Ferroptosis (hsa04216)
  Cellular senescence (hsa04218)
  Wnt signaling pathway (hsa04310)
  Neurotrophin signaling pathway (hsa04722)
  Thyroid hormone signaling pathway (hsa04919)
  Parkinson disease (hsa05012)
  Amyotrophic lateral sclerosis (hsa05014)
  Huntington disease (hsa05016)
  Shigellosis (hsa05131)
  Hepatitis C (hsa05160)
  Hepatitis B (hsa05161)
  Measles (hsa05162)
  Human cytomegalovirus infection (hsa05163)
  Human papillomavirus infection (hsa05165)
  Human T-cell leukemia virus 1 infection (hsa05166)
  Kaposi sarcoma-associated herpesvirus infection (hsa05167)
  Herpes simplex virus 1 infection (hsa05168)
  Epstein-Barr virus infection (hsa05169)
  Pathways in cancer (hsa05200)
  Transcriptional misregulation in cancer (hsa05202)
  Viral carcinogenesis (hsa05203)
  Proteoglycans in cancer (hsa05205)
  MicroRNAs in cancer (hsa05206)
  Colorectal cancer (hsa05210)
  Pancreatic cancer (hsa05212)
  Endometrial cancer (hsa05213)
  Glioma (hsa05214)
  Prostate cancer (hsa05215)
  Thyroid cancer (hsa05216)
  Basal cell carcinoma (hsa05217)
  Melanoma (hsa05218)
  Bladder cancer (hsa05219)
  Chronic myeloid leukemia (hsa05220)
  Small cell lung cancer (hsa05222)
  Non-small cell lung cancer (hsa05223)
  Breast cancer (hsa05224)
  Hepatocellular carcinoma (hsa05225)
  Gastric cancer (hsa05226)
  Central carbon metabolism in cancer (hsa05230)
  Lipid and atherosclerosis (hsa05417)
  Fluid shear stress and atherosclerosis (hsa05418)
• Reactome Pathway:
  Activation of PUMA and translocation to mitochondria (R-HSA-139915)
  Pre-NOTCH Transcription and Translation (R-HSA-1912408)
  Oxidative Stress Induced Senescence (R-HSA-2559580)
  Formation of Senescence-Associated Heterochromatin Foci (SAHF) (R-HSA-2559584)
  Oncogene Induced Senescence (R-HSA-2559585)
  DNA Damage/Telomere Stress Induced Senescence (R-HSA-2559586)
  SUMOylation of transcription factors (R-HSA-3232118)
  Autodegradation of the E3 ubiquitin ligase COP1 (R-HSA-349425)
  Association of TriC/CCT with target proteins during biosynthesis (R-HSA-390471)
  Pyroptosis (R-HSA-5620971)
  TP53 Regulates Metabolic Genes (R-HSA-5628897)
  Ub-specific processing proteases (R-HSA-5689880)
  Ovarian tumor domain proteases (R-HSA-5689896)
  Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks (R-HSA-5693565)
  Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807)
  TP53 Regulates Transcription of DNA Repair Genes (R-HSA-6796648)
  TP53 Regulates Transcription of Genes Involved in Cytochrome C Release (R-HSA-6803204)
  TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain (R-HSA-6803205)
  TP53 Regulates Transcription of Caspase Activators and Caspases (R-HSA-6803207)
  TP53 Regulates Transcription of Death Receptors and Ligands (R-HSA-6803211)
  TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest (R-HSA-6804114)
  TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain (R-HSA-6804115)
  TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest (R-HSA-6804116)
  Regulation of TP53 Expression (R-HSA-6804754)
  Regulation of TP53 Activity through Phosphorylation (R-HSA-6804756)
  Regulation of TP53 Degradation (R-HSA-6804757)
  Regulation of TP53 Activity through Acetylation (R-HSA-6804758)
  Regulation of TP53 Activity through Association with Co-factors (R-HSA-6804759)
  Regulation of TP53 Activity through Methylation (R-HSA-6804760)
  PI5P Regulates TP53 Acetylation (R-HSA-6811555)
  G2/M DNA damage checkpoint (R-HSA-69473)
  G2/M Checkpoints (R-HSA-69481)
  Stabilization of p53 (R-HSA-69541)
  Transcriptional activation of cell cycle inhibitor p21 (R-HSA-69895)
  The role of GTSE1 in G2/M progression after G2 checkpoint (R-HSA-8852276)
  Transcriptional Regulation by VENTX (R-HSA-8853884)
  RUNX3 regulates CDKN1A transcription (R-HSA-8941855)
  Regulation of PTEN gene transcription (R-HSA-8943724)
  Loss of function of TP53 in cancer due to loss of tetramerization ability (R-HSA-9723905)
  Factors involved in megakaryocyte development and platelet production (R-HSA-983231)
  Activation of NOXA and translocation to mitochondria (R-HSA-111448)

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PC14586	DMSJ54W	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

References

• [1] Clinical pipeline report, company report or official report of PMV Pharmaceuticals.